Ep 2: Prognostication of patients with corona...

In this Redcliffe Cardiology NVM reflections episode, Prof Nicolas Van Mieghem cuts through the noise from TCT 2025. Tune in to hear what the SELUTION trials mean for drug-coated balloons in de novo disease and ISR, why cost and sizing matter in calcium modification, how PE throm ...  Show more

At TCT 2025, Dr Nadira Hamid (Minneapolis Heart Institute, US) and Dr. Rahul P. Sharma (Stanford University, US) review the late-breaking trial data shaping the future of structural heart disease. The discussion highlights real-world results from TRISCEND and TRILUMINATE in tricu ...  Show more

In patients with heart failure with low ejection fraction and chronic coronary disease without unstable symptoms, does stenting open blocked coronary arteries extend life or reduce hospitalizations? There is some literature to suggest those with low EF may benefit from revascular ...  Show more

The ORBITA sham-control PCI study, Watchman, revascularization in cardiogenic shock, Absorb BVS, quality-of-life outcomes after PCI or bypass, and chronic total occlusion PCI are discussed in this week's podcast. 

Ischemia vs anatomic testing for CAD, UK-TAVI trial, TAVI for AR? and post-PCI anti-thrombotics are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. <u>To read a partial transcript or to commen ...

<span style= "color: #000000; font-family: helvetica; font-size: 10pt; white-space: normal; background-color: #ffffff; float: none; display: inline;"> <span style= "color: #000000; font-family: helvetica; font-size: small; white-space: normal; background-color: #ffffff; float: ...